EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies

Ding Jingnuo iD, Zhang Huachuan, Zhou Da, Ding Zhi, Chen Yan iD, Zhao Fazhi iD

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Ding Jingnuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Gastrointestinal Neoplasms. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Sichuan Cancer Hospital Outstanding Youth Fund, Chen Xiao Ping Foundation For The Development Of Science and Technology Of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal stromal tumors (GISTs), the most common mesenchymal neoplasms of the digestive tract, are primarily driven by gain‐of‐function mutations in the receptor tyrosine kinases KIT or PDGFRA. The introduction of imatinib, a selective tyrosine kinase inhibitor (TKI), revolutionized the management of advanced GIST. However, the emergence of drug resistance remains a major clinical challenge, limiting long‐term efficacy. Resistance mechanisms are multifactorial, predominantly involving secondary mutations in KIT or PDGFRA that impair TKI binding or stabilize the kinase in an active conformation. Beyond genomic alterations, nonmutational adaptive responses—including dysregulation of noncoding RNAs, metabolic reprogramming, epigenetic modifications, and an immunosuppressive tumor microenvironment—significantly contribute to treatment failure. This review comprehensively analyzes these resistance pathways and discusses the evolution of therapeutic strategies toward precision medicine. Current approaches emphasize molecular subtype‐guided first‐line therapy, ctDNA‐driven sequencing of subsequent lines, and the use of novel TKIs (e.g., avapritinib, ripretinib, bezuclastinib) tailored to specific resistance mutations. Furthermore, we explore emerging modalities such as boron neutron capture therapy (BNCT), which offers a kinase‐independent mechanism to target resistant disease, and combination strategies that integrate immunotherapy, epigenetic modulators, and pathway‐specific inhibitors. Advances in liquid biopsy and molecular profiling are enabling real‐time adaptation of therapy, moving GIST management toward a dynamic, personalized paradigm aimed at overcoming resistance and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsDrug Resistance, NeoplasmProtein Kinase InhibitorsGastrointestinal NeoplasmsHumansProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaPrecision MedicineTumor MicroenvironmentMutationMolecular Targeted TherapyEpigenesis, GeneticImatinib MesylateAntineoplastic AgentsImmunotherapyTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

boron neutron capture therapy (BNCT)epigenetic modulationgastrointestinal stromal tumors (GISTs)precision medicinetyrosine kinase inhibitor (TKI) resistance

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaImatinib MesylateAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of General Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
  • Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan Provinc…
  • Department of Gastric Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan Province…
  • Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, Peo…

ORCID-Profile: Ding Jingnuo, Chen Yan, Zhao Fazhi

Förderung

  • Sichuan Cancer Hospital Outstanding Youth Fund
  • Chen Xiao Ping Foundation For The Development Of Science and Technology Of Hubei Province

Zitieren

APA

Jingnuo, D., Huachuan, Z., Da, Z., Zhi, D., Yan, C., & Fazhi, Z. (2026). Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70306

Vancouver

Jingnuo D, Huachuan Z, Da Z, Zhi D, Yan C, Fazhi Z. Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70306

BibTeX
@article{Jingnuo2026,
  author = {Jingnuo, Ding and Huachuan, Zhang and Da, Zhou and Zhi, Ding and Yan, Chen and Fazhi, Zhao},
  title = {Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70306}
}
Kostenlos starten →